UnitedHealthcare (Commercial) · percutaneous vertebral augmentation
✓ conditional · commercial
Criteria checklist
0 of 6 ticked- enumerated: yes
- covered:
- name: Painful vertebral body fracture/lesion within 4 months of onset, failed optimal medical therapy
- criteria:
- onset window: within 4 months of pain onset
- functional impairment: required
- etiologies:
- osteoporotic VCF
- steroid-induced fracture
- osteolytic metastatic disease
- multiple myeloma
- vertebral hemangioma with aggressive features
- unstable osteonecrosis (Kummell)
- imaging: CT/MRI rules out other pain causes (foraminal stenosis, HNP, other generators)
- excluded must be absent:
- spinal cord compression on CT/MRI
- significant collapse/destruction (vertebra <1/3 original height)
- healed VCF; asymptomatic VCF; VCF responding to conservative therapy
- sacral/coccygeal lesions
- required: yes
- min duration months: not stated in the policy
- satisfied by:
- failed Optimal Medical Therapy within the 4-month window
- contraindicated
- modalities named:
- analgesics / medical therapy
- activity modification
- bracing
- required: no
- min duration days: not stated in the policy
- success criteria: not stated in the policy
- threshold is binding: no
- required: no
- must clear: no
- note posture: not required
- applies: no
UHC commercial vertebral augmentation policy. Covers a painful vertebral fracture/lesion WITHIN 4 MONTHS of pain onset that has failed optimal medical therapy (osteoporotic, steroid-induced, osteolytic mets, myeloma, aggressive hemangioma, Kummell), with CT/MRI excluding other pain causes. KEY divergence from Medicare: a hard <=4-month onset window, and it does NOT require MR marrow-edema / STIR or bone-scan positivity (which the Medicare LCDs emphasize). Excluded: cord compression, severe collapse (vertebra reduced to <1/3 of its original height), healed/asymptomatic VCF, sacral/coccygeal lesions. From the actual fetched UHC PDF.
Ticks are a documentation aid — nothing is stored; they reset on reload.
Dot phrase
Self-contained narrative A&P attestation. `***` = fill-in. Maps to UHC commercial policy 2026T0581Q (Percutaneous Vertebroplasty and Kyphoplasty). The hard gate is the <=4-MONTH onset window — date the pain onset in the note.
.KYPHOUHC Assessment: *** — painful vertebral body fracture or lesion at ***, WITHIN 4 MONTHS of pain onset (onset ***), with functional impairment. Etiology: *** (osteoporotic VCF / steroid-induced fracture / osteolytic metastatic disease / multiple myeloma / vertebral hemangioma with aggressive features / unstable osteonecrosis [Kummell]). CT/MRI on *** rules out other causes of pain including foraminal stenosis, disc herniation, and other generators. Medical necessity per UHC 2026T0581Q: optimal medical therapy within the 4-month window has failed or was contraindicated — analgesics and medical therapy, activity modification, and bracing: *** . All exclusions are absent: there is no spinal cord compression on CT/MRI, no significant collapse or destruction (the vertebra is NOT reduced to <1/3 of its original height), the fracture is not healed, not asymptomatic, and not responding to conservative therapy, and this is not a sacral or coccygeal lesion. Plan: Percutaneous *** (kyphoplasty 22513 thoracic / 22514 lumbar [+22515 each add'l]; or vertebroplasty 22510-22512) at level(s) ***, under imaging guidance. Risks, benefits, and alternatives discussed; consent obtained.
Where this payor diverges from the Medicare baseline
Cautions
Prior-auth pathway
- required: not stated in the policy
- note: not stated in-policy; governed by a separate UHC PA list
Provenance
- authority:
- type: commercial_policy
- id: UHC 2026T0581Q
- title: Percutaneous Vertebroplasty and Kyphoplasty — Commercial and Individual Exchange
- applies because: UHC commercial medical policy governs vertebral augmentation (criteria in-policy)
- source: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/percutaneous-vertebroplasty-kyphoplasty.pdf
- archived copy:
sources/uhc_vertaug_2026-03-01.pdf(sha256 98e4a6ed14ca… — kept in the content repo, not served here) - effective: 2026-03-01 · payor last reviewed: 2026-03-01 · we verified: 2026-07-24 · v1
Change history
- 2026-07-24commercial cells: re-verify 27 source PDFs by SHA-256 (Carelon/eviCore/UHC/Cigna) - all unchanged vs committed archive; last_verified -> 2026-07-24
3615c231f0 - 2026-07-23kyphoplasty/uhc: prose said '>1/3 height loss' — source says vertebra <1/3 original height
5d96842aa2 - 2026-06-30Archive commercial source PDFs into sources/ + wire source_file/source_hash
c5466694c8 - 2026-06-28Add commercial Vertebral Augmentation cells: Anthem, UHC, Cigna
ee451f0955